Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss

Frisone, D; Charrier, M; Clement, S; Christinat, Y; Thouvenin, L; Homicsko, K; Michielin, O; Bodmer, A; Chappuis, PO; McKee, TA; Tsantoulis, P

Frisone, D (reprint author), Hop Univ Geneve, Dept Oncol, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland.

CANCER BIOLOGY & THERAPY, 2020; 21 (3): 197

Abstract

Alterations of the Retinoblastoma (Rb) pathway are frequent in ovarian cancer, typically resulting from CDKN2A down-regulation, CCNE1 amplification, CCND1/2 amplification, and RB1 loss. However, bi-allelic CDKN2A mutation or homozygous deletion is a very rare event, concerning less than 5% of patients. Initial trials with palbociclib in serous ovarian cancer have shown very modest benefit in unselected patient populations, thus underlining the need for a biomarker predicting response. We report the case of a heavily pre-treated patient with a serous ovarian tumor harboring a homozygous deletion of the CDKN2A gene that derived significant, prolonged clinical benefit from palbociclib, a CDK4/6 oral inhibitor, with letrozole. Treatment with palbociclib and letrozole started on February 2018, with an ongoing response after 12 months. In conclusion, homozygous CDKN2A deletion is rare and could be used to predict response to CDK4/6 inhibitors in association with other genomic features. We encourage further trials in this direction.

Download PDF


Full Text Link